Abstract: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: There is provided an antiviral vinyl-chloride-based resin composition including: 100 parts by weight of a poly(vinyl chloride)-based resin obtained by mixing 10-90 parts by weight of a vinyl-chloride-based resin for paste with 90-10 parts by weight of a suspension vinyl-chloride-based resin; and 0.5-10.0 parts by weight of a sulfonic-acid-based surfactant.

Abstract: The present invention disclosed herein relates to synergistic compositions for cerebrovascular diseases. In particular, the invention relates to synergistic, efficient, composition for treating cerebral ischemia or stroke comprising specific combination of standardized celery seed extract (CSE) enriched with Dl-3-N-Butylphthalide (NBP) and SIRT1 activators, wherein D1-3-N-Butylphthalide (NBP) and SIRT1 activator are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

Abstract: A compound 1,3-benzothiazol-2-yl-N?-[(3-phenylprop-2-enoyl)oxy]ethanimidamide, its synthesis, and its use as an anticancer and/or antimicrobial agent.

Abstract: The present invention provides new GABAA receptor-binding compounds that modify the activation of GABAA, their use in the preparation of a neuroactive pharmaceutical composition, improving sperm motility and labeling of biomolecules.

Abstract: The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Abstract: In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.

Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

Abstract: Provided herein are compositions and methods for treating pulmonary hypertension. In particular, provided herein are dry powder formulations of fasudil for delivery to the lung.

Abstract: Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclosed.

Abstract: A conjugate comprising a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, characterised in that the linker includes at least two ˜(CH2—CH2—O—)˜ units within a ring, said ring being attached via a single tethering atom within the ring to the rest of the linker, or said ring being attached via two or more tethering atoms within the ring to the rest of the linker at a single point.

Abstract: A compound 1,3-benzothiazol-2-yl-N?-[(naphthalene-1-carbonyl)oxy]ethanimidamide compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.

Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract: Embodiments of the disclosure relate to dosage forms intended for smoking, vaporization and/or inhalation and to methods for the preparations thereof.

Abstract: Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.

Abstract: Provided herein is a drug eluting device that can be implanted into the Muller's muscle of a subject to elute a sympathetic stimulant such as oxymetazoline, phenylephrine, norepinephrine, adrenaline, or a combination thereof. Also provided herein are methods to use the device and sympathetic stimulant to treat or prevent eyelid ptosis.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: The present invention belongs to the area of pharmaceutical and cosmetic compositions and refers to compounds, novel mixtures and preparations comprising certain compound(s) of formula (I) which show anti-inflammatory properties.